People with thalassemia trait usually don’t have any symptoms. In certain cases, like during pregnancy, thalassemia carriers may have symptoms of mild anemia, such as fatigue or headaches. Thalassemia ...

The thalassemias are an inherited group of heterogeneous anemias in which 1 or more of the globin chains in the hemoglobin tetramer are absent. Among the 4 classic alpha thalassemia syndromes, there ...

When we think about common health issues, diabetes and high blood pressure are the most common health issues that pop into our minds. However, some other disorders are more common than we think and ...

Feeling tired and weak all the time and having pale or yellowish skin may be connected to your genes. Alpha thalassemia is an inherited blood disorder in which specific gene mutations that get passed ...

People with the thalassemia trait, or thalassemia carriers, may not experience any symptoms. However, some thalassemia carriers can experience anemia symptoms, such as paleness and fatigue. In people ...

Thalassemia is a common genetic condition affecting red blood cells. Children with severe forms of thalassemia often develop symptoms early in life, but effective treatment can manage the condition.

Researchers from Mahidol University have developed a rapid, high-throughput screening method for prevention and control of thalassemia. The related report by Munkongdee et al, "Rapid diagnosis of ...

Thalassemia is an inherited blood disorder that affects the production of hemoglobin and red blood cells. Symptoms include jaundice, chest pain, breathing problems, and more. Various complications can ...

CHULA VISTA, Calif. — Nothing can prepare you for parenthood, and a local family was not ready to hear their unborn child may die or have life long complications. For Annemarie and Stephen, they were ...

Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for mitapivat in the treatment of adults with non-transfusion-dependent (NTD) and ...